SRR934878
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.667
- G2M_CHECKPOINT+0.633
- MYC_TARGETS_V1+0.604
- MYC_TARGETS_V2+0.546
- INTERFERON_ALPHA_RESPONSE+0.498
- UNFOLDED_PROTEIN_RESPONSE+0.421
- MTORC1_SIGNALING+0.408
- INTERFERON_GAMMA_RESPONSE+0.406
- ALLOGRAFT_REJECTION+0.403
- DNA_REPAIR+0.393
Top 10 suppressed
- KRAS_SIGNALING_DN-0.406
- MYOGENESIS-0.337
- PANCREAS_BETA_CELLS-0.239
- ESTROGEN_RESPONSE_EARLY-0.231
- HEDGEHOG_SIGNALING-0.202
- XENOBIOTIC_METABOLISM-0.170
- APICAL_SURFACE-0.167
- SPERMATOGENESIS-0.132
- ESTROGEN_RESPONSE_LATE-0.129
- BILE_ACID_METABOLISM-0.126
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.936 |
| 2 | 31A652B1-3BEB-4D78-BCA0-4C153EBC41E8 | — | — | 0.931 |
| 3 | SRR934927 | — | — | 0.930 |
| 4 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.915 |
| 5 | D717EAB5-3C67-4EF0-99BF-3416278BE492 | — | — | 0.914 |
| 6 | SRR934964 | — | — | 0.913 |
| 7 | SRR934975 | — | — | 0.912 |
| 8 | SRR934851 | — | — | 0.911 |
| 9 | 2E040577-EA0C-4876-9F43-A180DA38F733 | — | — | 0.909 |
| 10 | SRR934922 | — | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.667 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.633 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.604 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.546 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.498 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.421 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.408 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.406 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.403 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.393 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.388 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.387 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.307 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.299 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.279 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.216 | Inavolisib | — uncovered |
| COMPLEMENT | 0.215 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.214 | Inavolisib | — uncovered |
| APOPTOSIS | 0.204 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.204 | Inavolisib | — uncovered |